CIBMTR announces collaboration with Kite to track long-term outcomes data for YESCARTA

0

MINNEAPOLIS, Minn., May 17, 2018 – A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T cell (CAR T) therapies is formed between the CIBMTR® (Center for International Blood and Marrow Transplant Research), and Kite, a Gilead Company. CIBMTR is an organization that collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide. Under the terms of the agreement, CIBMTR will collect and analyze long-term safety and efficacy data for YESCARTA® in a commercial setting.

YESCARTA® is the first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. YESCARTA® is not indicated for the treatment of patients with primary central nervous system lymphoma.

"We are delighted to announce this partnership with Kite, a pioneer in the emerging cell therapy field," said Mary M. Horowitz, M.D., Chief Scientific Director of CIBMTR. "This collaboration will leverage CIBMTR's deep experience collecting and analyzing data on both the short and long-term outcomes of patients receiving complex cellular therapies, initially gleaned during our work supporting the development of HCT, the first, and for many years the only, successful cellular therapy for cancer. We look forward to expanding into the field of targeted cellular therapy and to contributing to efforts to better understand the potential for these therapies to improve outcomes for patients with cancer."

CIBMTR is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW). Together, CIBMTR and Be The Match BioTherapies®, a subsidiary of NMDP/Be The Match, offer end-to-end solutions for developers of cell therapies, including cell sourcing and collection, clinical trial services, supply chain logistics, manufacturing and commercialization support, and outcomes management.

###

About CIBMTR

The CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW). The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide to increase survival and enrich quality of life for patients. The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database.

Contacts

CIBMTR
Andrea Kusch
Communications Consultant
414-805-0665
[email protected]

NMDP/Be The Match
Melissa Neill
Supervisor, PR and Social Media
763-406-8762
[email protected]

MCW
Holly Botsford
External Relations Manager
414-955-8761
[email protected]

Media Contact

Melissa Neill
[email protected]

http://https://bethematch.org/

https://bethematchbiotherapies.com/about-us/news-and-events/cibmtr-announces-collaboration-with-kite-to-track-long-term-outcomes-data-for-yescarta/?utm_source=eurekalert&utm_medium=press_release&utm_campaign=cibmtr_pr

Leave a Reply

%d bloggers like this: